Drug Discovery World
JULY 20, 2023
Compounds can be printed neat at 10mM in dimethyl sulfoxide (DMSO), and a unique data point is generated per target-ligand interaction. PROTAC), and training AI drug discovery models. billion compounds, deep library annotation and ready-designed panels sorted by different molecule types and target groups.
The Pharma Data
JANUARY 6, 2021
Next-generation digital technologies are having an immense impact on the drug discovery process. The pharma industry is witnessing a steep rise in the use of AI-driven solutions in early-stage drug discovery, deep-learning technologies for compound screening, and lead identification and automation enhancements in the lab.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
OCTOBER 4, 2022
Using its proprietary compound screening platform, Oligomerix discovers and develops differentiated, oral, small molecule inhibitors of tau self-association that are easy to administer and cost-effective. . The post Taking a new approach to tackle neurodegenerative diseases appeared first on Drug Discovery World (DDW).
Drug Discovery World
JANUARY 23, 2023
In 2020, AI models predicted the efficacy of repurposed drugs for Covid-19. Our core technology uses machine learning (ML) models on image-based measurements of cellular morphology to broadly explore biology and chemistry and accelerate drug discovery efforts. Clinical trials revealed eight out of nine predictions were correct.
Drug Discovery World
AUGUST 15, 2023
Can potentially lethal arrhythmias induced by novel drugs be better predicted by using more relevant and sophisticated electrophysiological screening methods? Such techniques, if routinely deployed in drug discovery, may enable improved decision making in predicting serious adverse cardiovascular events.
Drug Discovery World
JANUARY 26, 2023
Even when those assets are excluded, the average ROI for 2021 was still double the 2022 projections.   “Aside from Covid-19, the fall in projected ROI has been driven by a combination of factors, ranging from high-value drugs securing approvals and entering commercialisation, to an increase in cycle times for drugs still in development.
Drug Discovery World
FEBRUARY 22, 2024
This article is sponsored by Collaborative Drug Discovery. About Collaborative Drug Discovery CDD provides a modern approach to drug discovery informatics that is trusted globally by thousands of leading researchers. For more information, visit www.collaborativedrug.com.
Expert insights. Personalized for you.
40 
Let's personalize your content